148 related articles for article (PubMed ID: 37850770)
21. Musculoskeletal complications of sickle cell disease in Enugu, Nigeria.
Onyemaechi NO; Enweani UN; Maduka CO
Niger J Med; 2011; 20(4):456-61. PubMed ID: 22288323
[TBL] [Abstract][Full Text] [Related]
22. Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus.
Yang Y; Kumar S; Lim LS; Silverman ED; Levy DM
J Rheumatol; 2015 Dec; 42(12):2304-9. PubMed ID: 26568601
[TBL] [Abstract][Full Text] [Related]
23. An update on the recent literature on sickle cell bone disease.
Osunkwo I
Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):539-46. PubMed ID: 24150191
[TBL] [Abstract][Full Text] [Related]
24. Sickle Cell Disease and Psychosocial Well-Being: Comparison of Patients With Preclinical and Clinical Avascular Necrosis of the Femoral Head.
Tezol O; Karahan F; Unal S
Turk Arch Pediatr; 2021 Jul; 56(4):308-315. PubMed ID: 35005723
[TBL] [Abstract][Full Text] [Related]
25. Osteonecrosis in sickle cell disease patients from Bahia, Brazil: a cross-sectional study.
Daltro G; Franco BA; Faleiro TB; Rosário DAV; Daltro PB; Fortuna V
Int Orthop; 2018 Jul; 42(7):1527-1534. PubMed ID: 29582115
[TBL] [Abstract][Full Text] [Related]
26. The incidence, risk factors, and outcomes of symptomatic avascular necrosis of bone among Chinese pediatric patients with acute lymphoblastic leukemia.
Hoo CPL; Leung AWK; Chan JPK; Cheung YT; Cheng FWT; Chow TTW; Lam GKS; Ha SY; Chiang AKS; Li RCH; Li CK
Cancer Med; 2023 May; 12(9):10315-10325. PubMed ID: 37000036
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics of avascular necrosis in patients with Behçet disease: a case series and literature review.
Atas N; Bitik B; Varan O; Babaoglu H; Tufan A; Haznedaroglu S; Goker B; Ozturk MA
Rheumatol Int; 2019 Jan; 39(1):153-159. PubMed ID: 30560445
[TBL] [Abstract][Full Text] [Related]
28. Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: A retrospective case-control study.
Faezi ST; Hoseinian AS; Paragomi P; Akbarian M; Esfahanian F; Gharibdoost F; Akhlaghi M; Nadji A; Jamshidi AR; Shahram F; Nejadhosseinian M; Davatchi F
Mod Rheumatol; 2015 Jul; 25(4):590-4. PubMed ID: 25528860
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium.
Dampier C; LeBeau P; Rhee S; Lieff S; Kesler K; Ballas S; Rogers Z; Wang W;
Am J Hematol; 2011 Feb; 86(2):203-5. PubMed ID: 21264908
[TBL] [Abstract][Full Text] [Related]
30. Treatment for avascular necrosis of bone in people with sickle cell disease.
Martí-Carvajal AJ; Solà I; Agreda-Pérez LH
Cochrane Database Syst Rev; 2009 Jul; (3):CD004344. PubMed ID: 19588352
[TBL] [Abstract][Full Text] [Related]
31. Sickle cell bone disease and response to intravenous bisphosphonates in children.
Grimbly C; Escagedo PD; Jaremko JL; Bruce A; Alos N; Robinson ME; Konji VN; Page M; Scharke M; Simpson E; Pastore YD; Girgis R; Alexander RT; Ward LM
Osteoporos Int; 2022 Nov; 33(11):2397-2408. PubMed ID: 35904681
[TBL] [Abstract][Full Text] [Related]
32. Autologous bone marrow stromal cells are promising candidates for cell therapy approaches to treat bone degeneration in sickle cell disease.
Lebouvier A; Poignard A; Coquelin-Salsac L; Léotot J; Homma Y; Jullien N; Bierling P; Galactéros F; Hernigou P; Chevallier N; Rouard H
Stem Cell Res; 2015 Nov; 15(3):584-594. PubMed ID: 26492634
[TBL] [Abstract][Full Text] [Related]
33. Avascular Necrosis of Bone in Patients with Uveitis Treated with Systemic Corticosteroids.
Wong SW; Steeples LR; Jones NP
Ocul Immunol Inflamm; 2022 May; 30(4):869-875. PubMed ID: 33539719
[TBL] [Abstract][Full Text] [Related]
34. Treatment for avascular necrosis of bone in people with sickle cell disease.
Martí-Carvajal AJ; Solà I; Agreda-Pérez LH
Cochrane Database Syst Rev; 2016 Aug; (8):CD004344. PubMed ID: 27502327
[TBL] [Abstract][Full Text] [Related]
35. Treatment for avascular necrosis of bone in people with sickle cell disease.
Martí-Carvajal AJ; Solà I; Agreda-Pérez LH
Cochrane Database Syst Rev; 2014 Jul; (7):CD004344. PubMed ID: 25009086
[TBL] [Abstract][Full Text] [Related]
36. Closed bone graft epiphysiodesis for avascular necrosis of the capital femoral epiphysis.
Thompson GH; Lea ES; Chin K; Liu RW; Son-Hing JP; Gilmore A
Clin Orthop Relat Res; 2013 Jul; 471(7):2199-205. PubMed ID: 23389802
[TBL] [Abstract][Full Text] [Related]
37. Natural course of talar avascular necrosis during short-term follow-up and factors associated with Disease progression.
Choi YH; Kwon TH; Choi JH; Lee DY; Lee KM
BMC Musculoskelet Disord; 2024 Jan; 25(1):85. PubMed ID: 38254084
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Bone Microarchitectural Changes and Structural Damage in Sickle Cell Disease-Induced Avascular Necrosis Using Raman Spectroscopy: Is there potential for medical management?
Al-Ghaithi A; Husband J; Al-Maskari S
Sultan Qaboos Univ Med J; 2021 May; 21(2):e297-e301. PubMed ID: 34221479
[TBL] [Abstract][Full Text] [Related]
39. Treatment of AVN Using Autologous BM Stem Cells and Activated Platelet-Derived Growth Factor Concentrates.
Nandeesh NH; Janardhan K; Subramanian V; Ashtekar AB; Srikruthi N; Koka PS; Deb K
J Stem Cells; 2016; 11(3):135-148. PubMed ID: 28296878
[TBL] [Abstract][Full Text] [Related]
40. Characterization of opioid use in sickle cell disease.
Han J; Zhou J; Saraf SL; Gordeuk VR; Calip GS
Pharmacoepidemiol Drug Saf; 2018 May; 27(5):479-486. PubMed ID: 28815799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
